Ofloxacin 200 mg
Ornidazole 500 mg
Ofloxacin belongs to a class of drugs called quinolone antibiotics. It works by stopping the growth of bacteria. This medication is used to treat a variety of bacterial infections.
Ornidazole is a C-nitro compound that is 5-nitroimidazole in which the hydrogen at positions 1 and 2 are replaced by 3-chloro-2-hydroxypropyl and methyl groups, respectively. It is used in the treatment of susceptible protozoal infections and for the treatment of anaerobic bacterial infections. It has a role as an antiprotozoal drug, an antiinfective agent, an antibacterial drug, an antitrichomonal drug and an epitope. It is a member of imidazoles, a C-nitro compound, a secondary alcohol and an organochlorine compound
- Bladder infection
- kidney infection
- inflammation of the urethra
- Pneumonia (lung infection)
- GIT infections
- Dental infections
- Gynecological infections
- ENT infections
- Surgical infections
The recommended dose for Zoxaquin-OZ is one tablet twice daily
Ofloxacin is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria. It functions by inhibiting DNA gyrase, a type II topoisomerase, and topoisomerase IV, which is an enzyme necessary to separate (mostly in prokaryotes, in bacteria in particular) replicated DNA, thereby inhibiting bacterial cell division.
Ornidazole: After passive absorption into bacterium cell, the nitro group of ornidazole is reduced to an amine group by ferrodoxin-type redox systems. The formation of redox intermediate intracellular metabolites is believed to be the key component responsible for killing microorganisms.
The administration of oral doses to fasting volunteers was followed by a rapid and almost complete absorption of ofloxacin. The peak plasma concentration after a single oral dose of 200mg averaged 2.6 µg/ml and was reached within one hour. The plasma elimination half-life was 5.7 to 7.0 hours and was not dose related.
The apparent distribution volume was 120 litres. The plasma concentration did not materially rise with repeat doses (accumulation factor for twice daily dosage: 1.5). The plasma protein binding was approx. 25%.
The Metabolism of ofloxacin was below 5%. The two main metabolites found in the urine were N-desmethyl-ofloxacin and ofloxacin-N-oxide.
Excretion is primarily renal. Between 80 and 90% of the dose were recovered from the urine as unchanged substance.
- pregnant or breast feeding women
- Seizure disorder
- Kidney disease
- Liver disease
- Mental disorders